Greenwich LifeSciences (GLSI) Competitors $10.08 -0.73 (-6.75%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$10.65 +0.57 (+5.64%) As of 07/15/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRMEShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors Zevra Therapeutics Tyra Biosciences Taysha Gene Therapies Opthea Bicycle Therapeutics Kura Oncology Septerna Abivax Maze Therapeutics Prime Medicine Greenwich LifeSciences (NASDAQ:GLSI) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Is GLSI or ZVRA more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -450.87% -333.18% Zevra Therapeutics -226.78%-201.05%-53.55% Do institutionals & insiders have more ownership in GLSI or ZVRA? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer GLSI or ZVRA? Greenwich LifeSciences presently has a consensus price target of $39.00, suggesting a potential upside of 286.90%. Zevra Therapeutics has a consensus price target of $23.71, suggesting a potential upside of 85.41%. Given Greenwich LifeSciences' higher probable upside, equities research analysts plainly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media favor GLSI or ZVRA? In the previous week, Zevra Therapeutics had 15 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 16 mentions for Zevra Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.79 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Overall Sentiment Greenwich LifeSciences Very Positive Zevra Therapeutics Positive Which has preferable valuation and earnings, GLSI or ZVRA? Greenwich LifeSciences has higher earnings, but lower revenue than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.00Zevra Therapeutics$23.61M29.62-$105.51M-$1.90-6.73 Which has more volatility and risk, GLSI or ZVRA? Greenwich LifeSciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. SummaryZevra Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.51M$2.96B$5.61B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-8.0020.2228.5219.58Price / SalesN/A290.74426.1793.37Price / CashN/A43.1536.0257.93Price / Book53.057.568.135.54Net Income-$15.79M-$55.11M$3.24B$257.73M7 Day Performance-4.45%3.81%0.20%-0.08%1 Month Performance9.57%11.60%5.98%8.09%1 Year Performance-36.24%-2.11%26.15%13.02% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences2.154 of 5 stars$10.08-6.8%$39.00+286.9%-35.6%$144.51MN/A-8.003Positive NewsHigh Trading VolumeZVRAZevra Therapeutics3.0538 of 5 stars$11.27+15.7%$23.14+105.3%+105.3%$532.58M$23.61M-5.9320News CoverageAnalyst RevisionHigh Trading VolumeTYRATyra Biosciences3.1086 of 5 stars$9.61-3.9%$30.83+220.8%-49.5%$530.90MN/A-5.9020TSHATaysha Gene Therapies3.9896 of 5 stars$2.34-4.5%$8.20+250.4%+2.9%$525.92M$8.33M-6.88180OPTOpthea0.3863 of 5 stars$3.41+7.2%$1.33-60.9%+63.2%$524.84M$120K0.008Gap UpBCYCBicycle Therapeutics3.3819 of 5 stars$7.17-3.5%$25.00+248.7%-66.0%$514.56M$35.28M-2.28240KURAKura Oncology4.5592 of 5 stars$5.68-3.1%$24.50+331.3%-73.1%$507.33M$53.88M-2.70130SEPNSepterna1.5318 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/AABVXAbivax2.2435 of 5 stars$7.95-0.1%$31.00+289.9%-35.6%$505.10MN/A0.0061News CoveragePositive NewsHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121PRMEPrime Medicine3.7479 of 5 stars$3.80+22.2%$10.08+165.4%-25.8%$498.92M$3.85M-1.85234High Trading Volume Related Companies and Tools Related Companies ZVRA Competitors TYRA Competitors TSHA Competitors OPT Competitors BCYC Competitors KURA Competitors SEPN Competitors ABVX Competitors MAZE Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLSI Stock Alerts